EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic yield of next-generation sequencing for detecting monogenic familial hypercholesterolemia in uzbek patients with coronary artery disease

Rano B Alieva, Aleksandr B Shek iD, Anastasiya V Bahachova, Khurshid G Fozilov, Guzal J Abdullaeva, Alisher A Abdullaev, Lilya E Kan, Shavkat U Khoshimov, Andrey R Kim, Ulugbek I Nizamov, Dilnora B Yusupalieva

PLOS One · 09.07.2026 · 21 (7) · e0353401

DOI: 10.1371/journal.pone.0353401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 09.07.2026. Verfasst von Rano B Alieva und 10 weiteren Autor:innen. Beteiligte Einrichtung: Republican Specialized Scientific and Practical Medical Center for Cardiology, Ministry of Health of the Republic Uzbekistan, Tashkent, Uzbekistan. Hauptthemen laut MEDLINE: Coronary Artery Disease, High-Throughput Nucleotide Sequencing, Hyperlipoproteinemia Type II. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education, Science and Innovation of the Republic Uzbekistan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Familial hypercholesterolaemia (FH) is an inherited disorder with markedly elevated LDL-C and increased risk of premature atherosclerotic cardiovascular disease, most often caused by pathogenic variants in LDLR and less frequently APOB / PCSK9 (or recessive LDLRAP1 ). FH is commonly assessed using the Dutch Lipid Clinic Network (DLCN) score (definite >8, probable 6–8, possible 3–5). In Uzbekistan, genetic evidence for FH remains limited and largely based on candidate-variant studies, and the diagnostic yield of NGS for monogenic FH in CAD patients is not well defined.

Aim

For the first time in Uzbekistan and Central Asia, to investigate FH-associated monogenic variants using next-generation sequencing (NGS) and to assess the validity of the DLCN criteria against genetic testing as the diagnostic reference standard in Uzbek patients with CAD and suspected FH.

Methods

This study included 95 patients with coronary artery disease (CAD) who underwent targeted NGS of LDLR , APOB , PCSK9 , and LDLRAP1 . The suspected/phenotypic FH group comprised 56 patients: 53 with DLCN-predicted heterozygous FH (HeFH)—possible (3–5 points, n = 22), probable (6–8 points, n = 16), and definite (>8 points, n = 15)—and 3 siblings from one family with a homozygous FH (HoFH) phenotype. The control group included 39 CAD patients with hypercholesterolemia without an FH diagnosis (DLCN 1–2 points). Only pathogenic/likely pathogenic (P/LP) variants were used for genetic confirmation of FH.

Results

Pathogenic/likely pathogenic variants were detected in 10/53 (18.9%) DLCN-predicted HeFH patients and in all three HoFH siblings. Genetic confirmation rates (PPV) were 46.7% (7/15) in definite HeFH, 12.5% (2/16) in probable HeFH, and 4.5% (1/22) in possible HeFH; no P/LP variants were detected in controls (0/39). Using a DLCN >8 threshold, sensitivity was 70.0% (7/10) and specificity was 90.2% (74/82) in the CAD cohort excluding the HoFH family.

Conclusion

NGS confirmed the highest diagnostic yield in patients with DLCN >8, supporting its use as a practical threshold to prioritise genetic testing; however, monogenic FH may still be present in patients with probable or possible DLCN scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseHigh-Throughput Nucleotide SequencingHyperlipoproteinemia Type IIHumansFemaleMaleMiddle AgedProprotein Convertase 9UzbekistanReceptors, LDLGenetic TestingAdaptor Proteins, Signal TransducingApolipoprotein B-100AgedAdultApolipoproteins B

Substanzen

Proprotein Convertase 9PCSK9 protein, humanReceptors, LDLLDLRAP1 protein, humanAdaptor Proteins, Signal TransducingApolipoprotein B-100Apolipoproteins BLDLR protein, human

Autor:innen und Institutionen

  • Republican Specialized Scientific and Practical Medical Center for Cardiology, Ministry of Health of the Republic Uzbekistan, Tashkent, Uzbekistan.
  • Independent Consultant, Tbilisi, Georgia.
  • Center for Advanced Technologies, Ministry of Higher Education, Science and Innovation of the Republic Uzbekistan, Tashkent, Uzbekistan.

ORCID-Profile: Aleksandr B Shek

Förderung

  • Ministry of Higher Education, Science and Innovation of the Republic Uzbekistan

Zitieren

APA

Alieva, R. B., Shek, A. B., Bahachova, A. V., Fozilov, K. G., Abdullaeva, G. J., Abdullaev, A. A., Kan, L. E., Khoshimov, S. U., Kim, A. R., Nizamov, U. I., & Yusupalieva, D. B. (2026). Genetic yield of next-generation sequencing for detecting monogenic familial hypercholesterolemia in uzbek patients with coronary artery disease. PLOS One, 21(7), e0353401. https://doi.org/10.1371/journal.pone.0353401

Vancouver

Alieva RB, Shek AB, Bahachova AV, Fozilov KG, Abdullaeva GJ, Abdullaev AA, et al. Genetic yield of next-generation sequencing for detecting monogenic familial hypercholesterolemia in uzbek patients with coronary artery disease. PLOS One. 2026;21(7):e0353401. doi:10.1371/journal.pone.0353401

BibTeX
@article{Alieva2026,
  author = {Alieva, Rano B and Shek, Aleksandr B and Bahachova, Anastasiya V and Fozilov, Khurshid G and Abdullaeva, Guzal J and Abdullaev, Alisher A and Kan, Lilya E and Khoshimov, Shavkat U and Kim, Andrey R and Nizamov, Ulugbek I and Yusupalieva, Dilnora B},
  title = {Genetic yield of next-generation sequencing for detecting monogenic familial hypercholesterolemia in uzbek patients with coronary artery disease},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {7},
  pages = {e0353401},
  doi = {10.1371/journal.pone.0353401}
}
Kostenlos starten →